GENPREX (GNPX) Competitors $0.22 -0.01 (-4.09%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.22 +0.01 (+3.24%) As of 05:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. GBIO, FGEN, SCYX, OKUR, JATT, RNTX, TPST, LSTA, NNVC, and TENXShould you be buying GENPREX stock or one of its competitors? The main competitors of GENPREX include Generation Bio (GBIO), FibroGen (FGEN), SCYNEXIS (SCYX), OnKure Therapeutics (OKUR), JATT Acquisition (JATT), Rein Therapeutics (RNTX), Tempest Therapeutics (TPST), Lisata Therapeutics (LSTA), NanoViricides (NNVC), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. GENPREX vs. Its Competitors Generation Bio FibroGen SCYNEXIS OnKure Therapeutics JATT Acquisition Rein Therapeutics Tempest Therapeutics Lisata Therapeutics NanoViricides Tenax Therapeutics Generation Bio (NASDAQ:GBIO) and GENPREX (NASDAQ:GNPX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk. Do analysts recommend GBIO or GNPX? Generation Bio presently has a consensus price target of $37.33, indicating a potential upside of 460.56%. Given Generation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Generation Bio is more favorable than GENPREX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Generation Bio 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67GENPREX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GBIO or GNPX more profitable? GENPREX has a net margin of 0.00% compared to Generation Bio's net margin of -341.12%. Generation Bio's return on equity of -91.07% beat GENPREX's return on equity.Company Net Margins Return on Equity Return on Assets Generation Bio-341.12% -91.07% -33.65% GENPREX N/A -664.65%-370.18% Do institutionals and insiders believe in GBIO or GNPX? 95.2% of Generation Bio shares are held by institutional investors. Comparatively, 14.1% of GENPREX shares are held by institutional investors. 21.8% of Generation Bio shares are held by insiders. Comparatively, 0.4% of GENPREX shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, GBIO or GNPX? GENPREX has lower revenue, but higher earnings than Generation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneration Bio$19.89M2.26-$131.67M-$10.82-0.62GENPREXN/AN/A-$21.11MN/AN/A Does the media favor GBIO or GNPX? In the previous week, Generation Bio had 8 more articles in the media than GENPREX. MarketBeat recorded 11 mentions for Generation Bio and 3 mentions for GENPREX. GENPREX's average media sentiment score of 0.44 beat Generation Bio's score of -0.23 indicating that GENPREX is being referred to more favorably in the news media. Company Overall Sentiment Generation Bio Neutral GENPREX Neutral Which has more risk & volatility, GBIO or GNPX? Generation Bio has a beta of 2.67, meaning that its stock price is 167% more volatile than the S&P 500. Comparatively, GENPREX has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. SummaryGeneration Bio beats GENPREX on 10 of the 13 factors compared between the two stocks. Get GENPREX News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGENPREXMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.46M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / SalesN/A356.37470.61115.79Price / CashN/A43.0338.2159.48Price / Book1.448.608.866.15Net Income-$21.11M-$54.65M$3.25B$265.06M7 Day Performance1.03%5.86%3.72%2.60%1 Month Performance-27.17%8.86%5.86%2.83%1 Year Performance-66.87%13.33%30.49%25.58% GENPREX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGENPREX1.489 of 5 stars$0.22-4.1%N/A-70.4%$7.46MN/A0.0020Earnings ReportShort Interest ↑GBIOGeneration Bio3.3131 of 5 stars$4.15-3.0%$80.00+1,827.7%-71.4%$28.83M$19.89M-0.38150News CoverageEarnings ReportAnalyst ForecastGap DownFGENFibroGen4.6157 of 5 stars$7.94+11.7%$43.00+441.6%+4.6%$28.72M$29.62M-3.18570Earnings ReportHigh Trading VolumeSCYXSCYNEXIS1.5776 of 5 stars$0.88+19.5%N/A-51.4%$28.56M$3.75M-1.5660News CoverageEarnings ReportGap UpHigh Trading VolumeOKUROnKure Therapeutics3.4546 of 5 stars$2.01-1.5%$32.33+1,508.6%N/A$27.56MN/A-0.38N/AEarnings ReportJATTJATT AcquisitionN/A$1.57+7.5%N/A-51.7%$27.08MN/A0.003Gap UpHigh Trading VolumeRNTXRein TherapeuticsN/A$1.11-3.9%N/AN/A$26.62MN/A-0.399News CoverageEarnings ReportTPSTTempest Therapeutics2.247 of 5 stars$7.03-0.6%$30.00+326.7%-38.7%$26.03MN/A-0.3920Negative NewsEarnings ReportLSTALisata Therapeutics2.2915 of 5 stars$2.80-5.4%$23.50+739.3%-11.1%$25.50M$1M-1.2230Short Interest ↑Analyst RevisionGap DownNNVCNanoViricides0.3107 of 5 stars$1.58-0.6%N/A-23.0%$25.39MN/A-2.1920TENXTenax Therapeutics1.9868 of 5 stars$5.98-2.1%$17.50+192.6%+50.6%$25.35MN/A-2.419News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies GBIO Competitors FGEN Competitors SCYX Competitors OKUR Competitors JATT Competitors RNTX Competitors TPST Competitors LSTA Competitors NNVC Competitors TENX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENPREX Please log in to your account or sign up in order to add this asset to your watchlist. Share GENPREX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access